$EXAI News
Last published 1w ago
- 1w agoEXAIEarnings Call - EXSCIENTIA PLCEarnings Call Transcriptsyou you you you you you you you Thank you. Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA IGC Annual Meeting in Denver. Today, we'll sh
- 1mo agoEXAIRecursion - 1773714 - EXSCIENTIA PLCEarnings Call TranscriptsGood morning, everyone. I'm Sean Larman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley. Welcome to our Global Healthcare Conference. Before we commence, I'll make you aware of some important disclosures. F
- 1mo agoEXAIMorgan Stanley 24th Annual Global Healthcare Conference - EXSCIENTIA PLCEarnings Call TranscriptsGood morning, everyone. I'm Sean Larman, Head of US Mid-Cap Biotech Equity Research at Morgan Stanley. Welcome to our Global Healthcare Conference. Before we commence, I'll make you aware of some important disclosures. F
- 3mo agoEXAI2026 SMID CAP EXECUTIVE INSIGHTS EVENT (VIRTUAL) - EXSCIENTIA PLCEarnings Call TranscriptsHi, everyone. I'm Jill Hall, head of U.S. Small and Mid-Cap Strategy here at BVA Global Research. So just wanted to welcome everyone to our day one of our virtual Mid-Cap event. Excited to hear from corporates across the
- 3mo agoEXAIEarnings Call - EXSCIENTIA PLCEarnings Call Transcriptsyou you Thank you for watching! Good morning, everyone, and thank you for joining us. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements. Next slide. Please refer
- 4mo agoEXAIRECURSION PHARMACEUTICALS, INC. ANNUAL MEETING OF STOCKHOLDERS - EXSCIENTIA PLCEarnings Call TranscriptsGood afternoon and welcome to Recursion Pharmaceuticals' 2026 Annual Meeting of Stockholders. I'm Nizhat Khan, Chief Executive Officer and President of Recursions, and a member of the Board of Directors. I will preside a
- 6mo agoEXAIEarnings Call - EXSCIENTIA PLCEarnings Call TranscriptsThank you. Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question. How do we harness the full power of AI to consistently and with urgency create bet
- 1y agoEXAIRXRXRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryGlobeNewswireRecursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and
- 1y agoEXAIRXRXRecursion and Exscientia Shareholders Approve the Proposed CombinationGlobeNewswireSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination
- 2y agoEXAIExscientia Achieves Milestones for Two Programmes in Sanofi CollaborationBusiness WireBoth programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600
- 2y agoEXAIExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024Business WireDemonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD
- 2y agoRXRXEXAIRecursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatmentCNBCRecursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
- 2y agoEXAIRLYBData Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual MeetingBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data
- 2y agoBLFYGEHCEXAIRXRXAI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech BoomPR NewswireUSA News Group – Health care is undergoing a tech revolution, with health systems increasingly leveraging artificial intelligence (AI) bots for...
- 2y agoEXAIExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness WireExscientia plc (NASDAQ:EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare
- 2y agoEXAIExscientia Business Update for Second Quarter and First Half 2024Business WireEntered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial
- 2y agoAVAIEXAIIQVRXRX+1How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market UpdatesGlobeNewswirePALM BEACH, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards
- 2y agoEXAIRXRXRecursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesGlobeNewswireBrings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first,
- 2y agoEXAILatest Updates of Viva Biotech's Portfolio CompaniesPR NewswireEven with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term...
- 2y agoEXAIExscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data ReadoutBusiness WireMaximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination
- 2y agoEXAIExscientia Launches AWS AI-powered Platform to Advance Drug DiscoveryBusiness Wire— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia's ability to deliver high quality drug
- 2y agoEXAIINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaGlobeNewswireNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ:EXAI) and
- 2y agoEXAISHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the...
- 2y agoEXAIINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaGlobeNewswireNEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ:EXAI) and
- 2y agoEXAIExscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in OncologyBusiness Wire— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief
- 2y agoEXAIDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaGlobeNewswireNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ:EXAI) and
- 2y agoEXAIDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the...
- 2y agoEXAISHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaGlobeNewswireNEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ:EXAI) and
- 2y agoEXAIExscientia to Present at Upcoming Investor Conferences in JuneBusiness WireExscientia plc (NASDAQ:EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel
- 2y agoEXAIExscientia plc Sued for Securities Law Violations - Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAIPR NewswireThe Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the ...
- 2y agoEXAIExscientia plc Sued for Securities Law Violations - Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights – EXAIGlobeNewswireNEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ:EXAI). Shareholders who purchased shares of EXAI during the class period listed are
- 2y agoEXAIExscientia plc (EXAI) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoEXAIExscientia Business Update for First Quarter 2024Business WirePositive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into
- 2y agoEXAIShareholders of Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAIPR NewswireThe Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the ...
- 2y agoEXAIExscientia plc Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights – EXAIGlobeNewswireNEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ:EXAI). Shareholders who purchased shares of EXAI during the class period listed are
- 2y agoEXAIExscientia to Report First Quarter 2024 Financial Results on May 21, 2024Business WireCompany to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21,
- 2y agoEXAIExscientia plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAIPR NewswireThe Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the ...
- 2y agoEXAIInvestors in Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAIPR NewswireThe Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the ...
- 2y agoEXAIExscientia plc (EXAI) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoEXAIExscientia Business and Financial Update for the Full Year 2023Business WireExscientia plc (NASDAQ:EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will
- 2y agoEXAIExscientia to Report Full Year 2023 Financial Results on March 21, 2024Business WireCompany to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023,
- 2y agoEXAIExscientia to Present at Upcoming Investor Conferences in MarchBusiness WireExscientia plc (NASDAQ:EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on
- 2y agoEXAIExscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer PatientsBusiness WireMulticentre EXCYTE-2 study to evaluate precision medicine platform in patients with acute myeloid leukaemia Supports ongoing development of LSD1 inhibitor (EXS74539) currently in preclinical development Exscientia
- 2y agoEXAIProfessor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)Business WireDistinguished honour for Exscientia's founder and Chief Executive Awarded in the 2024 New Year Honours List by HM King Charles III Follows multiple recent recognitions for outstanding personal achievements and those
- 2y agoEXAIExscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia ProgrammeBusiness WireThe programme aims to design a potential best in class molecule by combining Exscientia's research platform with Sanofi's leading development expertise Exscientia eligible for additional upfront and research
- 2y agoEXAIExscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic InfluenzaBusiness Wire$2.3 million grant expected to drive research to harness the host interferon response as a pathway to treating and preventing pandemic influenza Exscientia plc (NASDAQ:EXAI) announced today that the Company received a
- 2y agoEXAIExscientia to Present at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness WireExscientia plc (NASDAQ:EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST
- 3y agoEXAIExscientia Business Update for Third Quarter 2023Business WireExscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a
- 3y agoEXAIExscientia to Report Third Quarter 2023 Financial Results on November 9, 2023Business WireCompany to host conference call and webcast on November 9, 2023, at 1:30 p.m. GMT / 8:30 a.m. EST Exscientia plc (NASDAQ:EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday,
- 3y agoEXAIParker Moss to Join Exscientia as EVP, Corporate DevelopmentBusiness WireRenowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice